Generalised Anxiety Disorder (GAD)

1. Clinical Overview

Generalised Anxiety Disorder (GAD) is characterised by excessive, persistent, and pervasive anxiety and worry about multiple domains of life (work, health, finances, family, minor matters) occurring on most days for at least 6 months. The worry is difficult to control, disproportionate to the actual likelihood or impact of anticipated events, and is accompanied by physical symptoms including muscle tension, restlessness, fatigue, difficulty concentrating, irritability, and sleep disturbance. [1,2]

GAD affects approximately 5-6% of people over their lifetime, with a 12-month prevalence of 2-3%. [3] It is the most common anxiety disorder in primary care and represents a significant burden due to its chronic, fluctuating course and substantial comorbidity with major depressive disorder (60-70% of cases) and other anxiety disorders. [4,5]

The disorder is associated with significant functional impairment, reduced quality of life, increased healthcare utilisation, and elevated cardiovascular risk. [6] Despite being highly prevalent and treatable, GAD remains under-recognised in clinical practice, with an average delay of 5-10 years between symptom onset and treatment initiation. [7]

Key Clinical Principles

"Free-Floating Anxiety": Unlike specific phobias (discrete feared object) or panic disorder (recurrent discrete attacks), GAD involves pervasive worry that shifts between multiple topics. Patients often describe feeling "constantly on edge" or "worrying about everything" without a specific trigger. This "free-floating" quality is characteristic. [1]

The Worry is the Problem: In GAD, the core issue is excessive worry itself, not the content of the worry. Patients recognise their worry is disproportionate but cannot control it. They spend a significant portion of each day worrying, which interferes with concentration, sleep, and daily functioning. [2]

Comorbidity is the Rule, Not the Exception: 60-90% of individuals with GAD have at least one comorbid psychiatric condition. Major depressive disorder is present in 60-70% at some point. Other anxiety disorders (panic disorder, social anxiety) occur in 50-60%. Substance use disorders, particularly alcohol misuse as self-medication, occur in 20-30%. Always screen for depression (PHQ-9) and alcohol use (AUDIT) in patients with GAD. [4,5]

---

2. Epidemiology

Prevalence and Incidence

Demographic Factors

Risk Factors

Genetic Factors:

• Heritability approximately 30% (modest compared to schizophrenia or bipolar disorder). [10]
• Shared genetic vulnerability with major depressive disorder (genetic correlation r=0.6). [10]
• Family history of anxiety or mood disorders increases risk 2-6 fold.

Developmental and Environmental Factors:

Personality Factors:

• Neuroticism: Strong association; tendency to experience negative emotions. [13]
• Intolerance of uncertainty: Core cognitive vulnerability; inability to tolerate ambiguity or unpredictability. [14]
• Perfectionism: Maladaptive perfectionism drives worry about performance and outcomes.

Comorbidity

GAD rarely occurs in isolation. Comorbid conditions significantly impact treatment response and prognosis. [4,5]

---

3. Pathophysiology

The pathophysiology of GAD involves complex interactions between genetic vulnerability, neurobiology, psychology, and environmental factors. [15]

Neurobiological Mechanisms

1. Amygdala Hyperactivity

The amygdala is the brain's "threat detection centre." In GAD, functional neuroimaging studies demonstrate:

• Hyperactivation of the amygdala in response to neutral or ambiguous stimuli (interpreted as threatening). [16]
• Reduced habituation to repeated stimuli (anxiety persists rather than diminishing with exposure).
• Hypervigilance: Enhanced processing of potential threats, even when objectively safe.

2. Prefrontal-Amygdala Dysconnectivity

The prefrontal cortex (PFC) normally provides top-down regulation of amygdala activity, allowing rational appraisal to "override" emotional threat responses. In GAD:

• Reduced PFC-amygdala connectivity: Impaired ability to downregulate amygdala activity through cognitive reappraisal. [17]
• Reduced ventromedial PFC activity: Associated with difficulty extinguishing fear responses.
• Perseverative worry: Without adequate prefrontal inhibition, threat-related cognitions persist.

3. Neurotransmitter Dysregulation

4. HPA Axis Dysregulation

• Chronic stress leads to HPA axis hyperactivity and cortisol dysregulation.
• Some studies show blunted cortisol response to acute stressors (allostatic load).
• Elevated cortisol may contribute to hippocampal volume reduction and memory impairment. [20]

Psychological Mechanisms

Cognitive Model (Wells, Borkovec)

Core Feature: Intolerance of Uncertainty [14]

Individuals with GAD have a reduced ability to tolerate uncertain or ambiguous situations. Worry functions as a maladaptive coping strategy to reduce uncertainty ("If I think through every possibility, I can prepare for the worst").

Worry as Cognitive Avoidance [21]

Paradoxically, worry (verbal-linguistic rumination) may serve to avoid more distressing emotional imagery. Abstract worrying is less physiologically activating than vivid mental imagery. Thus, worry "protects" from acute distress but maintains chronic anxiety by preventing habituation and emotional processing.

Metacognitive Beliefs [22]

Patients with GAD often hold:

• Positive beliefs about worry: "Worrying helps me prepare," "Worrying shows I care."
• Negative beliefs about worry: "Worry is uncontrollable," "Worry will make me ill."

These metacognitive beliefs maintain the worry cycle. Metacognitive therapy (MCT) targets these beliefs directly.

Safety Behaviours and Reassurance-Seeking

Common safety behaviours in GAD include:

• Excessive checking (locks, emails, health symptoms)
• Reassurance-seeking from family/doctors
• Avoidance of uncertainty-provoking situations
• Excessive planning and preparation

These behaviours provide short-term relief but maintain anxiety long-term by preventing disconfirmation of feared outcomes.

---

4. DSM-5 Diagnostic Criteria

The DSM-5 criteria for Generalised Anxiety Disorder are as follows. [1] All criteria must be met for diagnosis.

Criterion A: Excessive Anxiety and Worry

Excessive anxiety and worry (apprehensive expectation), occurring more days than not for at least 6 months, about a number of events or activities (such as work or school performance).

Criterion B: Difficulty Controlling Worry

The individual finds it difficult to control the worry.

Criterion C: Associated Symptoms (≥3 for Adults)

The anxiety and worry are associated with three (or more) of the following six symptoms (with at least some symptoms present more days than not for the past 6 months):

Note: Only one symptom is required in children.

Criterion D: Clinically Significant Distress or Impairment

The anxiety, worry, or physical symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.

Criterion E: Not Attributable to Substance or Medical Condition

The disturbance is not attributable to the physiological effects of a substance (e.g., drug of abuse, medication) or another medical condition (e.g., hyperthyroidism).

Criterion F: Not Better Explained by Another Mental Disorder

The disturbance is not better explained by another mental disorder, for example:

• Anxiety about having panic attacks (Panic Disorder)
• Negative evaluation in social situations (Social Anxiety Disorder)
• Contamination or other obsessions (OCD)
• Reminders of traumatic events (PTSD)
• Separation from attachment figures (Separation Anxiety Disorder)
• Gaining weight (Anorexia Nervosa)
• Physical complaints (Somatic Symptom Disorder)
• Perceived appearance flaws (Body Dysmorphic Disorder)
• Serious illness (Illness Anxiety Disorder)
• Content of delusional beliefs (Schizophrenia or Delusional Disorder)

Clinical Pearl: The "6-Month Rule"

The 6-month duration criterion distinguishes GAD from normal, transient worry related to identifiable stressors. However, patients often present before 6 months if distress is severe. In practice, if the clinical picture is otherwise consistent with GAD, treatment should not be delayed.

---

5. Clinical Presentation

Psychological Symptoms

Somatic (Physical) Symptoms

GAD is frequently associated with prominent somatic symptoms. Patients often present to primary care or emergency departments with physical complaints rather than psychological distress. [8]

Red Flags Requiring Urgent Assessment

[!CAUTION] Red Flags in Anxiety Presentations:

• Suicidal ideation or plans: Always assess suicide risk. GAD with comorbid depression carries significant suicide risk.
• Psychotic features: Hallucinations or delusions suggest alternative diagnosis (psychotic depression, schizophrenia).
• Sudden onset with prominent physical symptoms: Consider medical causes (thyroid storm, myocardial infarction, pulmonary embolism, phaeochromocytoma, hypoglycaemia).
• Confusion or altered consciousness: Consider delirium, intoxication, withdrawal.
• Severe self-neglect: Not eating, drinking, or self-caring due to anxiety.
• Severe functional impairment: Unable to work, leave house, or care for dependents.

---

6. Differential Diagnosis

Psychiatric Differential

Medical Differential

Always consider medical causes of anxiety symptoms, particularly with:

• New onset in older adults
• Prominent physical symptoms
• Atypical presentation
• Poor response to treatment

Substance-Induced Anxiety

---

7. Clinical Assessment

Structured Assessment

1. History of Presenting Complaint

• Onset and duration: When did worry begin? Acute or gradual? Duration > 6 months?
• Content of worry: What topics? (work, health, finances, relationships, minor matters)
• Severity: How much time spent worrying per day? Impact on functioning?
• Control: Can the patient "switch off" worry? Does worry intrude on other activities?
• Associated symptoms: DSM-5 Criterion C symptoms (restlessness, fatigue, concentration, irritability, muscle tension, sleep)
• Precipitants: Stressors, life events, changes?
• Course: Constant or fluctuating? Periods of remission?

2. Risk Assessment

• Suicidal ideation: Passive death wishes, active suicidal thoughts, plans, intent?
• Self-harm: Current or past?
• Self-neglect: Eating, drinking, self-care?
• Functional impairment: Work, relationships, activities of daily living?

3. Screen for Comorbidity

• Depression: PHQ-9. Low mood, anhedonia, hopelessness?
• Other anxiety disorders: Panic attacks, social anxiety, specific phobias, OCD, PTSD?
• Alcohol and substance use: AUDIT-C, CAGE. Using substances to manage anxiety?
• Eating disorders: Weight concerns, restriction, bingeing?

4. Medical and Drug History

• Medical conditions: Thyroid disease, cardiac disease, respiratory disease?
• Medications: Steroids, stimulants, beta-agonists, withdrawal from benzodiazepines or alcohol?
• Caffeine intake: Quantify daily intake.
• Substance use: Cannabis, stimulants, alcohol?

5. Family and Social History

• Family psychiatric history: Anxiety, depression, suicide?
• Social support: Living situation, relationships, employment?
• Functional status: Impact on work, relationships, daily activities?

Screening Tools

GAD-7 (Generalised Anxiety Disorder 7-item Scale)

The GAD-7 is the most widely used screening and monitoring tool for GAD. It is validated, brief (2 minutes), and recommended by NICE. [23]

Questions (rated 0-3: not at all, several days, more than half the days, nearly every day):

Over the last 2 weeks, how often have you been bothered by:

1. Feeling nervous, anxious, or on edge
2. Not being able to stop or control worrying
3. Worrying too much about different things
4. Trouble relaxing
5. Being so restless that it's hard to sit still
6. Becoming easily annoyed or irritable
7. Feeling afraid as if something awful might happen

Scoring:

Sensitivity and Specificity: At cutoff ≥10, sensitivity 89%, specificity 82% for GAD diagnosis. [23]

GAD-2 (Ultra-Brief Screen)

The first two items of GAD-7. Score ≥3 warrants full GAD-7 assessment.

1. Feeling nervous, anxious, or on edge
2. Not being able to stop or control worrying

PHQ-9 (Patient Health Questionnaire-9)

Screen for comorbid depression. Score ≥10 suggests moderate depression.

AUDIT-C

Screen for alcohol misuse. Score ≥5 (men) or ≥4 (women) indicates hazardous drinking.

Physical Examination

Physical examination is important to:

1. Exclude medical causes of anxiety symptoms
2. Establish baseline before pharmacotherapy

Investigations

Investigations serve to exclude medical causes. Not all patients require full investigation.

First-Line Investigations

Consider if Indicated

---

8. Management

Overview: NICE Stepped Care Model

The NICE guideline CG113 recommends a stepped care approach based on severity and response to treatment. [24]

GAD MANAGEMENT (NICE Stepped Care)
              |
              v
+-----------------------------------------------------+
|        STEP 1: ALL PATIENTS                         |
|                                                     |
| - Identification and assessment                     |
| - Psychoeducation (explain anxiety, course, Rx)     |
| - Active monitoring (2-4 weeks)                     |
| - Lifestyle advice:                                 |
|   * Regular exercise (≥30 min, 5x/week)             |
|   * Sleep hygiene                                   |
|   * Reduce caffeine and alcohol                     |
|   * Relaxation techniques                           |
| - Self-help resources (NHS apps, books)             |
+-----------------------------------------------------+
              |
              v (If no improvement or moderate severity)
+-----------------------------------------------------+
|        STEP 2: MILD-MODERATE GAD                    |
|                                                     |
| Low-intensity psychological intervention:           |
| - Guided self-help (CBT-based, 6+ weeks)            |
| - Psychoeducation groups                            |
| - Computerised CBT (e.g., SilverCloud)              |
|                                                     |
| OR if patient prefers medication:                   |
| - Consider SSRI (sertraline)                        |
+-----------------------------------------------------+
              |
              v (If inadequate response or severe)
+-----------------------------------------------------+
|        STEP 3: MODERATE-SEVERE / STEP 2 FAILED      |
|                                                     |
| High-intensity psychological therapy:               |
| - Individual CBT (12-16 sessions)                   |
| - Applied relaxation                                |
|                                                     |
| OR Pharmacotherapy (FIRST-LINE):                    |
| - SSRI: Sertraline 50mg → 200mg                     |
| - Other SSRIs: Escitalopram, paroxetine             |
|                                                     |
| SECOND-LINE (if SSRI fails after 8-12 weeks):       |
| - SNRI: Duloxetine 60-120mg or Venlafaxine 75-225mg |
| - Pregabalin 150-600mg/day                          |
|                                                     |
| Consider combination: CBT + medication              |
+-----------------------------------------------------+
              |
              v (If treatment-resistant)
+-----------------------------------------------------+
|        STEP 4: TREATMENT-RESISTANT / COMPLEX        |
|                                                     |
| - Refer to specialist mental health services        |
| - Review diagnosis (consider comorbidities)         |
| - Consider:                                         |
|   * Augmentation strategies                         |
|   * Buspirone (adjunct)                             |
|   * Pregabalin (if not tried)                       |
|   * Quetiapine (off-label, limited evidence)        |
|   * Intensive psychological therapy                 |
|                                                     |
| BENZODIAZEPINES: Short-term crisis only (less than 2-4 wks)  |
| NOT for routine or ongoing use (dependence risk)    |
+-----------------------------------------------------+

Psychological Therapies

Cognitive Behavioural Therapy (CBT)

The Gold Standard for GAD. CBT is recommended by NICE as a first-line treatment with Level 1a evidence. [24,25]

Core Components:

Format:

• Typically 12-16 sessions
• Weekly sessions of 50-60 minutes
• Can be delivered individually or in groups
• Guided self-help (bibliotherapy, computerised CBT) for mild-moderate GAD

Efficacy:

• Response rate: 50-60%
• Effect sizes: Large (Cohen's d = 0.8-1.2)
• Durable effects: Benefits maintained at 12-24 month follow-up [25]

Applied Relaxation

Applied relaxation is an evidence-based alternative to CBT, recommended by NICE when CBT is declined or unavailable. [24]

Technique:

• Progressive muscle relaxation training
• Cue-controlled relaxation (rapid relaxation to a cue word)
• Application of relaxation skills in anxiety-provoking situations

Efficacy: Comparable to CBT in some trials. Effect sizes moderate (d = 0.5-0.7). [26]

Mindfulness-Based Therapies

Mindfulness-Based Stress Reduction (MBSR) and Mindfulness-Based Cognitive Therapy (MBCT) show promise for GAD. [27]

Mechanism: Shifting relationship with worrying thoughts (observing rather than engaging). Reducing experiential avoidance.

Evidence: Moderate effect sizes. May be useful adjunct or alternative if CBT unavailable.

Metacognitive Therapy (MCT)

Targets metacognitive beliefs about worry ("Worrying helps me cope," "Worrying is uncontrollable"). [22]

Evidence: Emerging evidence of efficacy comparable to or exceeding CBT. Further research needed.

Pharmacotherapy

First-Line: SSRIs

Selective serotonin reuptake inhibitors (SSRIs) are first-line pharmacotherapy for GAD. [24,28]

Key Prescribing Points:

1. Warn about initial worsening: SSRIs can transiently increase anxiety in the first 1-2 weeks. Start at low dose and titrate slowly. [29]

2. Onset of action: 4-6 weeks for anxiolytic effect. Partial response may take 8-12 weeks. [24]

3. Adequate trial: Trial at adequate dose for 8-12 weeks before switching.

4. Duration: Continue for at least 12 months after remission to prevent relapse. Longer (2+ years) if recurrent episodes. [24]

5. Discontinuation: Taper gradually over 4+ weeks to minimise discontinuation symptoms.

Second-Line: SNRIs

Serotonin-noradrenaline reuptake inhibitors (SNRIs) are recommended if SSRI fails or is not tolerated. [24,28]

Second-Line: Pregabalin

Pregabalin is an alpha-2-delta ligand licensed for GAD in the UK/EU (not FDA-approved for GAD in USA). [31]

Mechanism: Reduces glutamate release by binding to alpha-2-delta subunit of voltage-gated calcium channels.

Advantages: Rapid onset, no sexual dysfunction, no serotonergic side effects.

Disadvantages: Dizziness, sedation, weight gain, peripheral oedema. Potential for misuse/dependence.

Other Agents

Benzodiazepines: Use with Caution

Benzodiazepines (e.g., diazepam, lorazepam) are not recommended for routine use in GAD. [24]

Indications: Short-term crisis intervention only (maximum 2-4 weeks) when symptoms are severe and other treatments not yet effective.

Risks:

• Tolerance (loss of effect)
• Dependence (physical and psychological)
• Withdrawal (rebound anxiety, seizures)
• Cognitive impairment
• Falls (especially elderly)
• Paradoxical disinhibition

If used:

• Shortest effective duration
• Lowest effective dose
• Clear plan for discontinuation
• Avoid in elderly, substance use history, personality disorder

Combination Therapy

For moderate-severe GAD, combination of CBT plus pharmacotherapy may be more effective than either alone, though evidence is mixed. [33]

Practical Approach:

• Start with patient preference (psychological vs pharmacological)
• If partial response, add the other modality
• Combination particularly useful for severe cases or significant comorbidity

Treatment-Resistant GAD

If inadequate response to first- and second-line treatments:

1. Review diagnosis: Is it truly GAD? Consider comorbidities (depression, PTSD, personality disorder, substance use).
2. Optimise current treatment: Adequate dose? Adequate duration? Adherence?
3. Switch within class: Try alternative SSRI or SNRI.
4. Switch between classes: SSRI to SNRI, or trial pregabalin.
5. Augmentation: Add buspirone to SSRI/SNRI.
6. Specialist referral: Complex cases require secondary care input.
7. Intensive psychological therapy: Longer-term or more intensive CBT.

---

9. Prognosis and Outcomes

Natural History

GAD is typically a chronic, fluctuating disorder. Without treatment, the course is characterised by: [7]

• Persistent symptoms: 50-60% still symptomatic at 5 years
• Waxing and waning: Symptoms fluctuate with life stressors
• Comorbidity development: Depression often develops as secondary condition
• Functional impairment: Ongoing impact on work, relationships, quality of life

Outcomes with Treatment

Relapse: 20-40% relapse after stopping treatment. Longer treatment duration and psychological therapy reduce relapse risk.

Prognostic Factors

---

10. Key Guidelines and Evidence

Major Guidelines

1. NICE CG113: Generalised Anxiety Disorder and Panic Disorder in Adults (2011, updated 2020). Stepped care model. CBT and SSRIs first-line. [24]

2. BAP Guidelines: British Association for Psychopharmacology evidence-based guidelines for anxiety disorders (2014). Detailed pharmacotherapy guidance. [28]

3. CANMAT Guidelines: Canadian Network for Mood and Anxiety Treatments (2014). First-line: CBT, SSRI, SNRI, pregabalin. [34]

4. APA Guidelines: American Psychiatric Association Practice Guidelines. Similar recommendations.

Landmark Evidence

Cuijpers et al. (2014): Meta-Analysis of Psychological Treatments [25]

Design: Meta-analysis of 41 RCTs (2,132 patients).

Key Findings:

• CBT shows large effect sizes (g = 0.84) compared to control
• Applied relaxation effective (g = 0.53)
• Effects durable at 12-month follow-up

Impact: Established CBT as evidence-based first-line psychological treatment.

Baldwin et al. (2014): BAP Pharmacotherapy Guidelines [28]

Design: Systematic review and expert consensus.

Key Findings:

• SSRIs (escitalopram, paroxetine, sertraline) and SNRIs (duloxetine, venlafaxine) first-line
• Pregabalin effective alternative
• Benzodiazepines not recommended for routine use

Impact: International reference for pharmacological management.

Spitzer et al. (2006): GAD-7 Validation [23]

Design: Validation study in 2,740 primary care patients.

Key Findings:

• GAD-7 sensitivity 89%, specificity 82% at cutoff ≥10
• Good correlation with anxiety severity measures
• Brief, feasible for routine clinical use

Impact: GAD-7 became standard screening tool worldwide.

---

11. Examination Focus

Common Written Exam Questions (MRCP/FRACP/MRCGP)

1. "Which is the first-line pharmacological treatment for GAD?"

Answer: SSRI (sertraline or escitalopram). NICE recommends sertraline first-line. Warn patient of initial transient anxiety worsening. Allow 4-6 weeks for effect. Trial adequate dose for 8-12 weeks before switching.

2. "A 35-year-old woman with GAD has not responded to 8 weeks of sertraline 150mg. What is the next step?"

Answer: Switch to an SNRI (duloxetine or venlafaxine) or trial pregabalin. Ensure adequate trial (8-12 weeks) and maximum tolerated dose first. Consider CBT if not already offered.

3. "What is the duration of treatment for GAD?"

Answer: Continue for at least 12 months after remission. Longer treatment (2+ years) if recurrent episodes or significant residual symptoms. Taper gradually on discontinuation.

4. "What are the DSM-5 diagnostic criteria for GAD?"

Answer:

• Excessive worry about multiple domains, most days, ≥6 months
• Difficulty controlling worry
• ≥3 of: restlessness, fatigue, concentration, irritability, muscle tension, sleep disturbance
• Clinically significant distress or impairment
• Not attributable to substances or medical condition
• Not better explained by another mental disorder

5. "What is the role of benzodiazepines in GAD?"

Answer: Not recommended for routine use. Short-term crisis intervention only (maximum 2-4 weeks). Risk of tolerance, dependence, cognitive impairment, falls. Use lowest dose, shortest duration.

OSCE/PACES Scenarios

Station: "This 42-year-old woman presents with 8 months of worry, poor sleep, and difficulty concentrating. Take a history and discuss management."

Approach:

1. Focused history:

   • Onset, duration, content of worry
   • DSM-5 Criterion C symptoms (restlessness, fatigue, concentration, irritability, muscle tension, sleep)
   • Impact on functioning
   • Risk assessment (suicide, self-harm)
   • Screen for comorbidity (depression, alcohol)
   • Medical and drug history (exclude medical causes)

2. Explain diagnosis:

   • "Based on your symptoms, I think you have Generalised Anxiety Disorder. This is a common condition where people experience excessive worry about many things, most days, along with physical symptoms like difficulty sleeping and muscle tension."

3. Discuss management:

   • "Treatment is very effective. We have two main approaches: talking therapy and medication. Both work well."
   • "The talking therapy is called CBT—Cognitive Behavioural Therapy. It helps you understand and change the thinking patterns that maintain anxiety."
   • "The medication option is an antidepressant called sertraline. Despite the name, it's very effective for anxiety. It takes 4-6 weeks to work fully."
   • "We could start with guided self-help if symptoms are mild-moderate, or go straight to CBT or medication for more severe symptoms."
   • "We also recommend lifestyle changes: regular exercise, reducing caffeine, good sleep habits."

4. Shared decision-making:

   • "What are your thoughts? Would you prefer to try talking therapy, medication, or both?"

Viva Voce Points

Opening Statement

"Generalised Anxiety Disorder is characterised by excessive, persistent worry about multiple domains of life occurring on most days for at least 6 months, associated with symptoms such as restlessness, fatigue, concentration difficulty, irritability, muscle tension, and sleep disturbance. It has a lifetime prevalence of 5-6% and is frequently comorbid with depression. First-line treatments are CBT and SSRIs, with a stepped care approach based on severity."

High-Yield Facts

• Prevalence: 5-6% lifetime, 2-3% 12-month. Female:Male 2:1.
• Core feature: Excessive worry that is difficult to control.
• DSM-5: Worry + ≥3 associated symptoms + ≥6 months + distress/impairment.
• Comorbidity: 60-70% have comorbid depression. Screen with PHQ-9.
• First-line Rx: CBT (gold standard) or SSRI (sertraline first-line NICE). [24]
• Duration: 12+ months after remission.
• Benzodiazepines: NOT for routine use. Short-term crisis only (less than 2-4 weeks).
• GAD-7: Screening tool. ≥10 suggests moderate-severe anxiety. [23]

---

12. Common Pitfalls and Mistakes

Mistake 1: "The patient is worried about their health, so it must be illness anxiety disorder."

Reality: Worry about health is common in GAD. The key distinction is that GAD involves worry about multiple domains (health, finances, work, relationships, minor matters), not exclusively focused on illness.

Correct approach: Ask about the content of worry across different areas of life. If worry is pervasive and spans multiple domains, consider GAD.

Mistake 2: "The patient has panic attacks, so it can't be GAD."

Reality: Panic attacks can occur in GAD. The distinction is that in panic disorder, the panic attacks are recurrent, unexpected, and the patient fears having more attacks. In GAD, panic attacks are situational and secondary to pervasive worry.

Correct approach: Assess the primary problem. Is it pervasive worry (GAD) or recurrent unexpected panic attacks (panic disorder)?

Mistake 3: "Starting sertraline at full dose for faster effect."

Reality: SSRIs can transiently worsen anxiety in the first 1-2 weeks. Starting at full dose increases risk of side effects and treatment discontinuation.

Correct approach: Start at low dose (e.g., sertraline 25-50mg) and titrate gradually. Warn patient of possible initial worsening.

Mistake 4: "Prescribing benzodiazepines for ongoing anxiety."

Reality: Benzodiazepines are not recommended for routine use in GAD due to tolerance, dependence, and cognitive impairment. They do not treat the underlying disorder.

Correct approach: Benzodiazepines for short-term crisis only (2-4 weeks maximum). Focus on SSRIs and CBT for ongoing treatment.

Mistake 5: "Stopping treatment after 3 months because the patient feels better."

Reality: Early discontinuation is a major cause of relapse. NICE recommends continuing treatment for at least 12 months after remission.

Correct approach: Educate patient about relapse risk. Continue treatment for 12+ months. Taper gradually when discontinuing.

---

13. Patient and Layperson Explanation

"What is Generalised Anxiety Disorder?"

"Generalised Anxiety Disorder, or GAD, is a condition where you feel anxious and worried most of the time, about many different things—work, health, family, finances, even small everyday matters. This worry is hard to control and goes on for months. Unlike normal stress that comes and goes, GAD is persistent and can significantly affect your daily life.

GAD also causes physical symptoms: trouble sleeping, feeling tired, difficulty concentrating, irritability, and muscle tension, especially in the neck and shoulders. Many people with GAD describe feeling 'on edge' or 'wound up' all the time."

"Why does it happen?"

"We don't fully understand what causes GAD, but it's likely a combination of factors:

• Genes: It runs in families to some extent.
• Brain chemistry: The brain's 'worry centre' (amygdala) may be overactive, and the part that calms it down (prefrontal cortex) may not be working as well.
• Life experiences: Stressful events, childhood adversity, or chronic stress can contribute.
• Personality: Some people are naturally more prone to worry."

"How is it treated?"

"The good news is that GAD is very treatable. There are two main approaches, and both work well:

1. Talking therapy (CBT): Cognitive Behavioural Therapy helps you understand the thinking patterns that keep anxiety going and teaches you practical strategies to manage worry. It's typically 12-16 weekly sessions. The benefits last even after therapy ends.

2. Medication: SSRI antidepressants like sertraline are very effective for anxiety (despite the name 'antidepressant'). They take 4-6 weeks to work fully. You may need to take them for 12 months or more.

3. Self-help: For milder symptoms, guided self-help programs, apps, and books can be helpful.

4. Lifestyle changes: Regular exercise, good sleep habits, reducing caffeine, and relaxation techniques all help."

"What can I expect?"

"Most people with GAD improve significantly with treatment. It takes several weeks for medication or therapy to work fully. You may need to try different approaches to find what works best for you.

GAD can come back, especially during stressful times, but the coping skills you learn in therapy help prevent and manage future episodes."

"When should I seek help?"

"See a doctor if:

• Anxiety is affecting your daily life, work, or relationships
• You're using alcohol or other substances to cope
• You're feeling hopeless or having thoughts of harming yourself
• You're experiencing panic attacks or physical symptoms that concern you"

---

14. References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th ed. Washington, DC: American Psychiatric Publishing; 2013.

2. Andrews G, Hobbs MJ, Borkovec TD, et al. Generalized worry disorder: a review of DSM-IV generalized anxiety disorder and options for DSM-V. Depress Anxiety. 2010;27(2):134-147. doi:10.1002/da.20658

3. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169-184. doi:10.1002/mpr.1359

4. Kessler RC, Gruber M, Hettema JM, Hwang I, Sampson N, Yonkers KA. Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up. Psychol Med. 2008;38(3):365-374. doi:10.1017/S0033291707002012

5. Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2005;35(12):1747-1759. doi:10.1017/S0033291705006069

6. Celano CM, Daunis DJ, Lokko HN, Campbell KA, Huffman JC. Anxiety disorders and cardiovascular disease. Curr Psychiatry Rep. 2016;18(11):101. doi:10.1007/s11920-016-0739-5

7. Yonkers KA, Dyck IR, Warshaw M, Keller MB. Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry. 2000;176:544-549. doi:10.1192/bjp.176.6.544

8. Wittchen HU, Kessler RC, Beesdo K, Krause P, Höfler M, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry. 2002;63 Suppl 8:24-34.

9. Roy-Byrne PP, Davidson KW, Kessler RC, et al. Anxiety disorders and comorbid medical illness. Gen Hosp Psychiatry. 2008;30(3):208-225. doi:10.1016/j.genhosppsych.2007.12.006

10. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry. 2001;158(10):1568-1578. doi:10.1176/appi.ajp.158.10.1568

11. Kessler RC, McLaughlin KA, Green JG, et al. Childhood adversities and adult psychopathology in the WHO World Mental Health Surveys. Br J Psychiatry. 2010;197(5):378-385. doi:10.1192/bjp.bp.110.080499

12. Clauss JA, Blackford JU. Behavioral inhibition and risk for developing social anxiety disorder: a meta-analytic study. J Am Acad Child Adolesc Psychiatry. 2012;51(10):1066-1075.e1. doi:10.1016/j.jaac.2012.08.002

13. Kotov R, Gamez W, Schmidt F, Watson D. Linking "big" personality traits to anxiety, depressive, and substance use disorders: a meta-analysis. Psychol Bull. 2010;136(5):768-821. doi:10.1037/a0020327

14. Dugas MJ, Gagnon F, Ladouceur R, Freeston MH. Generalized anxiety disorder: a preliminary test of a conceptual model. Behav Res Ther. 1998;36(2):215-226. doi:10.1016/s0005-7967(97)00070-3

15. Martin EI, Ressler KJ, Binder E, Nemeroff CB. The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Psychiatr Clin North Am. 2009;32(3):549-575. doi:10.1016/j.psc.2009.05.004

16. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry. 2007;164(10):1476-1488. doi:10.1176/appi.ajp.2007.07030504

17. Kim MJ, Loucks RA, Palmer AL, et al. The structural and functional connectivity of the amygdala: from normal emotion to pathological anxiety. Behav Brain Res. 2011;223(2):403-410. doi:10.1016/j.bbr.2011.04.025

18. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety. 2000;12 Suppl 1:2-19. doi:10.1002/1520-6394(2000)12:1+less than 2::AID-DA2> 3.0.CO;2-4

19. Nutt DJ, Malizia AL. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry. 2001;179:390-396. doi:10.1192/bjp.179.5.390

20. Staufenbiel SM, Penninx BW, Spijker AT, Elzinga BM, van Rossum EF. Hair cortisol, stress exposure, and mental health in humans: a systematic review. Psychoneuroendocrinology. 2013;38(8):1220-1235. doi:10.1016/j.psyneuen.2012.11.015

21. Borkovec TD, Alcaine OM, Behar E. Avoidance theory of worry and generalized anxiety disorder. In: Heimberg RG, Turk CL, Mennin DS, eds. Generalized Anxiety Disorder: Advances in Research and Practice. New York: Guilford Press; 2004:77-108.

22. Wells A. Metacognitive Therapy for Anxiety and Depression. New York: Guilford Press; 2009.

23. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-1097. doi:10.1001/archinte.166.10.1092

24. National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management. Clinical guideline [CG113]. Published January 2011. Updated June 2020. https://www.nice.org.uk/guidance/cg113

25. Cuijpers P, Sijbrandij M, Koole S, Huibers M, Berking M, Andersson G. Psychological treatment of generalized anxiety disorder: a meta-analysis. Clin Psychol Rev. 2014;34(2):130-140. doi:10.1016/j.cpr.2014.01.002

26. Ost LG. Applied relaxation: description of a coping technique and review of controlled studies. Behav Res Ther. 1987;25(5):397-409. doi:10.1016/0005-7967(87)90017-9

27. Hoge EA, Bui E, Marques L, et al. Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: effects on anxiety and stress reactivity. J Clin Psychiatry. 2013;74(8):786-792. doi:10.4088/JCP.12m08083

28. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403-439. doi:10.1177/0269881114525674

29. Sinclair LI, Christmas DM, Hood SD, et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry. 2009;194(6):483-490. doi:10.1192/bjp.bp.107.048371

30. Koponen H, Allgulander C, Erickson J, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry. 2007;9(2):100-107. doi:10.4088/pcc.v09n0203

31. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23(3):240-249. doi:10.1097/01.jcp.0000084032.22282.ff

32. Chessick CA, Allen MH, Thase M, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 2006;(3):CD006115. doi:10.1002/14651858.CD006115

33. Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77-84. doi:10.3109/13651501.2012.667114

34. Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14 Suppl 1:S1. doi:10.1186/1471-244X-14-S1-S1

---

Further Resources

• Anxiety UK: anxietyuk.org.uk
• Mind: mind.org.uk
• NICE CKS Generalised Anxiety Disorder: cks.nice.org.uk
• NHS Every Mind Matters: nhs.uk/every-mind-matters

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate guidelines and specialists for patient care.